Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
76,86 CHF | -1,00% |
|
-0,77% | -.--% |
Vakgebied
- oncologie (29,9%)
- immunologie (17,2%)
- cardiovasculaire, nier- en metabolische ziekten (14,1%);
- neurowetenschap (8,9%).
De resterende netto-omzet (29,9%) is afkomstig van contractproductie van farmaceutische producten.
Eind 2023 had Novartis AG wereldwijd 33 productielocaties.
De netto-omzet is geografisch als volgt verdeeld: Europa (33%), de Verenigde Staten (39,5%), Azië/Afrika/Australië (20,5%), Canada en Latijns-Amerika (7%).
Verkoop per activiteit
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Verkoop per regio
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4,28% |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26,41% |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25,63% |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25,94% |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1,73% |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23,04% |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17,90% |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27,09% |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26,88% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-01-05 | |
Director of Finance/CFO | 59 | 01-01-03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16-05-22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01-04-17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01-12-18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01-01-04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01-08-13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01-05-22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01-09-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01-01-13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28-02-20 |
Chairman | 68 | 01-01-13 | |
John Young
BRD | Director/Board Member | 60 | 07-03-23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 28-02-20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01-01-16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01-01-13 |
Nancy Andrews
BRD | Director/Board Member | 65 | 01-01-15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28-02-19 |
Frans van Houten
BRD | Director/Board Member | 64 | 28-02-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 2 189 930 497 | 1 866 336 959 ( 85,22 %) | 233 443 766 ( 10,66 %) | 85,22 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
NOVARTIS AG 6.63% | 145 083 991 | 6.63% | 14 983 623 163 $ |
MORPHOSYS AG 51.00% | 19 235 375 | 51.00% | 1 433 544 021 $ |
SANDOZ GROUP AG 2.99% | 12 886 900 | 2.99% | 457 966 018 $ |
NOVARTIS INDIA LIMITED 70.68% | 17 450 680 | 70.68% | 218 239 949 $ |
THIRD HARMONIC BIO, INC. 6.45% | 2 642 762 | 6.45% | 35 175 162 $ |
ERASCA, INC. 4.51% | 12 307 692 | 4.51% | 31 015 384 $ |
OCULIS HOLDING AG 4.66% | 1 713 521 | 4.66% | 20 151 007 $ |
MOLECULAR PARTNERS AG 4.74% | 1 739 130 | 4.74% | 6 554 381 $ |
413 581 | 5.97% | 5 335 195 $ |
Bedrijfsgegevens
![Adres Novartis AG(0QM7)](https://cdn.zonebourse.com/static/address/15946360.png)
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Novartis Healthcare Pvt Ltd.
![]() Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
| |
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. |
Pharmaceuticals: Major
|
Sandoz GmbH
![]() Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Alcon Ophthalmika GmbH
| |
EBEWE Pharma Ges.m.b.H. Nfg.KG
![]() EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Sector
Verkoop per activiteit
Verkoop per regio
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+48,05% | 765 mld. | |
-6,16% | 354 mld. | |
+20,63% | 331 mld. | |
+9,94% | 299 mld. | |
+18,87% | 248 mld. | |
-1,96% | 219 mld. | |
+5,48% | 164 mld. | |
-2,26% | 162 mld. | |
+0,57% | 123 mld. |
- Beurs
- Aandelen
- Koers NOVN
- Koers 0QM7
- Onderneming Novartis AG